amlexanox has been researched along with Glioblastoma in 1 studies
amlexanox: SRA-A antagonist;structure given in first source
amlexanox : A pyridochromene-derived monocarboxylic acid having an amino substituent at the 2-position, an oxo substituent at the 5-position and an isopropyl substituent at the 7-position.
Glioblastoma: A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, Y | 1 |
| Lu, J | 1 |
| Zhang, Z | 1 |
| Zhu, L | 1 |
| Dong, S | 1 |
| Guo, G | 1 |
| Li, R | 1 |
| Nan, Y | 1 |
| Yu, K | 1 |
| Zhong, Y | 1 |
| Huang, Q | 1 |
1 other study available for amlexanox and Glioblastoma
| Article | Year |
|---|---|
Amlexanox, a selective inhibitor of IKBKE, generates anti-tumoral effects by disrupting the Hippo pathway in human glioblastoma cell lines.
Topics: Aminopyridines; Animals; Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Cycle; Cell Line, T | 2017 |